Keywords: ucb, par, drug, xyza, performs, well, trials

UCB's PAR drug Xyza performs well in trials

Article | 05 December 2005

Print This

Belgian drugs and chemicals firm UCB says that a recent study of Xyzal (levocetirizine), its once-daily antihistamine, both provided relief ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in